Regeneron Pharmaceuticals, Inc.
NASDAQ Global SelectTotal Valuation
Regeneron Pharmaceuticals, Inc. carries a market capitalization of 63.06B, placing it among publicly traded companies globally. Its enterprise value stands at 74.23B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 63.06B |
| Enterprise Value | 74.23B |
Share Statistics
Regeneron Pharmaceuticals, Inc. currently has 105.02M shares outstanding.
| Shares Outstanding | 105.02M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Regeneron Pharmaceuticals, Inc. trades at a trailing price-to-earnings ratio of 18.15. The price-to-sales ratio is 5.38, and the price-to-book ratio stands at 2.20.
| PE Ratio | 18.15 |
| PS Ratio | 5.38 |
| PB Ratio | 2.20 |
| P/TBV Ratio | 2.66 |
| P/FCF Ratio | 15.61 |
| P/OCF Ratio | 16.01 |
Enterprise Valuation
On an enterprise value basis, Regeneron Pharmaceuticals, Inc. trades at an EV/EBITDA multiple of 16.98 and an EV/FCF ratio of 13.81. The EV/Sales ratio of 4.98 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 19.37 provides insight into valuation relative to core operating earnings.
| EV / Sales | 4.98 |
| EV / EBITDA | 16.98 |
| EV / EBIT | 19.37 |
| EV / FCF | 13.81 |
Financial Position
Regeneron Pharmaceuticals, Inc. maintains a current ratio of 3.57, meaning it holds 3.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 8.61, indicating elevated leverage, while an interest coverage ratio of 91.10 demonstrates strong ability to service its debt obligations.
| Current Ratio | 3.57 |
| Quick Ratio | 2.84 |
| Debt / Equity | 8.61 |
| Debt / EBITDA | 0.62 |
| Interest Coverage | 91.10 |
Financial Efficiency
Regeneron Pharmaceuticals, Inc. posts a return on equity of 12.86 and a return on invested capital of 9.93.
| Return on Equity (ROE) | 12.86 |
| Return on Assets (ROA) | 11.28 |
| Return on Invested Capital (ROIC) | 9.93 |
| Return on Capital Employed (ROCE) | 12.03 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 0.73 |
Taxes
Over the trailing twelve months, Regeneron Pharmaceuticals, Inc. has paid 733.50M in income taxes, reflecting an effective tax rate of 14.22.
| Income Tax | 733.50M |
| Effective Tax Rate | 14.22 |
Stock Price Statistics
Regeneron Pharmaceuticals, Inc.'s stock has gained approximately 17.11563% over the past 52 weeks. The 50-day moving average sits at 692.30, while the 200-day moving average is 696.46.
| Beta (5Y) | N/A |
| 52-Week Price Change | 17.11563% |
| 50-Day Moving Average | 692.30 |
| 200-Day Moving Average | 696.46 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Regeneron Pharmaceuticals, Inc. generated 14.92B in revenue and converted that into 4.42B in net income, yielding earnings per share of 41.05. EBITDA reached 4.37B, while operating income came in at 3.83B.
| Revenue | 14.92B |
| Gross Profit | 12.61B |
| Operating Income | 3.83B |
| Pretax Income | 5.16B |
| Net Income | 4.42B |
| EBITDA | 4.37B |
| EBIT | 3.83B |
| Earnings Per Share (EPS) | 41.05 |
Balance Sheet
Regeneron Pharmaceuticals, Inc. holds 8.75B in cash and equivalents against 2.71B in total debt, resulting in a net debt position of -976.40M. Total book value stands at 36.42B, with working capital of 13.10B providing operational flexibility.
| Cash & Cash Equivalents | 8.75B |
| Total Debt | 2.71B |
| Net Debt | -976.40M |
| Equity (Book Value) | 36.42B |
| Book Value Per Share | 350.57 |
| Working Capital | 13.10B |
Cash Flow
Regeneron Pharmaceuticals, Inc. produced 5.01B in operating cash flow over the past twelve months. After subtracting -322.00M in capital expenditures, free cash flow totaled 4.69B - equivalent to 45.15 per share.
| Operating Cash Flow | 5.01B |
| Capital Expenditures | -322.00M |
| Free Cash Flow | 4.69B |
| FCF Per Share | 45.15 |
Margins
Regeneron Pharmaceuticals, Inc. operates with a gross margin of 84.55, reflecting its pricing power and cost economics. The operating margin of 25.69 and net profit margin of 29.65 provide insight into operational efficiency.
| Gross Margin | 84.55 |
| Operating Margin | 25.69 |
| Pretax Margin | 34.56 |
| Profit Margin | 29.65 |
| EBITDA Margin | 29.31 |
Dividends & Yields
The company's payout ratio of 8.46 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 3.60 |
| Dividend Yield | N/A |
| Payout Ratio | 8.46 |
| Shareholder Yield | 4.27 |
| FCF Yield | 6.41 |
Scores
Regeneron Pharmaceuticals, Inc. posts an Altman Z-Score of 7.48, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 7.48 |